Managing Prenatal CMV Infection: New Trends and Treatment

Prenatal CMV screening has gained significant attention in recent years due to emerging evidence regarding antiviral effectiveness. Cytomegalovirus remains a leading cause of congenital neurosensory impairment globally. Recent studies from France highlight a major shift in how clinicians manage this infection during pregnancy. Consequently, more doctors are adopting proactive screening and treatment strategies to protect newborns.

Evolution of Prenatal CMV Screening Protocols

The landscape of prenatal CMV screening changed drastically after pivotal clinical trials demonstrated the benefits of antiviral therapy. Previously, many healthcare systems avoided systematic testing due to limited treatment options. However, recent data shows a significant increase in both routine screening and maternal requests for tests. For example, screening rates in the French cohort rose from 22% to 40% within just a few years. This shift reflects a growing awareness among both patients and providers about the risks of vertical transmission. Furthermore, early detection allows for timely intervention, which is crucial for improving neonatal outcomes.

Impact of Valacyclovir on Vertical Transmission

Valacyclovir has emerged as a cornerstone in the prevention of congenital CMV. Clinical data confirms that high-dose valacyclovir reduces vertical transmission by nearly two-thirds when administered during the first trimester. Clinicians typically prescribe a dosage of 8 grams per day to achieve these results. Therefore, many international centers now offer this therapy to women with primary infection in the periconceptional period. Additionally, the treatment appears well-tolerated by most pregnant women. Nevertheless, medical teams must monitor renal function closely during the course of therapy. This proactive approach significantly lowers the risk of fetal infection and subsequent complications like hearing loss.

Relevance to Clinical Practice in India

In India, CMV seroprevalence is exceptionally high, often exceeding 95% in the adult population. While most congenital cases result from non-primary infections, primary infections still pose a serious risk. Consequently, Indian obstetricians are increasingly considering the role of prenatal CMV screening in high-risk scenarios. Moreover, the availability of valacyclovir makes the management of early-pregnancy infections more feasible. Doctors should discuss the benefits and limitations of screening with their patients. By doing so, they can identify at-risk pregnancies earlier and potentially offer life-changing interventions for the infant.

Frequently Asked Questions

Q1: Does valacyclovir effectively prevent transmission to the fetus?

Yes, clinical studies indicate that high-dose valacyclovir can reduce the rate of vertical transmission by approximately 66% when started early in pregnancy.

Q2: Is routine prenatal CMV screening mandatory in all countries?

No, screening policies vary significantly by region. However, many countries are seeing a rise in systematic screening as new evidence for antiviral treatment becomes available.

References

1. Coste-Mazeau P et al. Changing trends in prenatal screening and treatment of cytomegalovirus infection in France: 7-year national cohort study (2017-2023). Ultrasound Obstet Gynecol. 2026 May 04. doi: 10.1002/uog.70223. PMID: 42076947.
2. Giannattasio A, et al. The effect of valacyclovir on secondary prevention of congenital cytomegalovirus infection: An individual patient data meta-analysis. Ultrasound Obstet Gynecol. 2024.
3. Singla N, et al. Congenital cytomegalovirus infection: Experience from a tertiary health care centre of North India. Asian Pac J Trop Dis. 2014.